Background: Candida is a genus of yeasts and is the most common cause of fungal infections worldwide. Candida spp. is the commonest cause of disseminated mycoses with reported mortality to be as high as 40–50%. They account for about 15% of total health care associated infections (HCAIs) and more than 72% of nosocomial mycoses.
Objective: This was a descriptive cross-sectional study and aimed to study the spread of device associated candida infection in ICU patients, and ability of candida infection associated with medical devices to form biofilm and multidrug resistance candida infection.
Patients and Methods: The present study was conducted in the Department of Microbiology at El-Hussien Hospital, Cairo, Egypt from September 2019 to January 2020 and included patients who were admitted to ICU for more than 48 h and were exposed to medical devices.
Results: Number of all patients in ICUs included in the present study was 205 cases. Half of them have no growth (52.7%), and the other half has either bacterial (32.7%), candidal (12.7%) or mixed infections (2%). Identification of types of candida in device associated infection according to CHRO Magar and API system showed no statistical significant difference. Fluconazole (FLU) was sensitive in 19 patients (63.3%), Posaconazole (Posa) was sensitive in 22 patients (73.3%), Voriconazole (Vori) was sensitive in 18 patients (60%) and Cuspofungin (Cuspo) was sensitive in 26 patients (86.7%).  According to the sensitivity results in patients with biofilm, Fluconazole (FLU) and Posaconazole (Posa) were sensitive in 2 patients (40%), while Voriconazole (Vori) and Cuspofungin (Cuspo) were sensitive in 3 patients (60%).
Conclusion: The increased incidence of systemic mycoses caused by candida infection in hospitalized patients is an important cause of morbidity and mortality worldwide, especially in critically ill patients. Biofilms play an important role in the perpetuation of these infections primarily with respect to their ability to adhere to various medical devices.